Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

UCB

Status: Completed

Conditions: Epilepsies, Partial

Study type: Observational

Funder types: Industry

Identifiers

NCT01098162

SP0973

Details and patient eligibility

About

The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®. The observed population will be only patients with one baseline antiepileptic drug. Seizure control and tolerability data will be evaluated.

Enrollment: 576 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient's treatment must be in accordance with the local marketing authorization (MA) for Vimpat®
• The decision to prescribe Vimpat® has to be made by the physician before and independently of his/her decision to include the patient in the study
• The Vimpat® treatment should have been started not longer than 2 weeks before study inclusion of the patient
• The patient must have a diagnosis of Epilepsy with Partial-Onset Seizures
• Based on the physician's clinical judgment, the patient's seizure activity is not controlled sufficiently on a current monotherapy and it is in the patient's best interest to be prescribed adjunctive Vimpat®

Exclusion criteria

In accordance with the Summary of Product Characteristics (SmPC)

Trial design

576 participants in 1 patient group

Vimpat®

Description:

Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.